SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:gu ;pers:(Wallin Anders 1950);pers:(Blennow Kaj 1958);conttype:(refereed)"

Sökning: LAR1:gu > Wallin Anders 1950 > Blennow Kaj 1958 > Refereegranskat

  • Resultat 1-10 av 43
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Andersson, Carl-Henrik, et al. (författare)
  • A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease
  • 2016
  • Ingår i: Journal of Alzheimer's Disease. - 1387-2877. ; 53:4, s. 1353-1363
  • Tidskriftsartikel (refereegranskat)abstract
    • Alzheimer's disease (AD) is a neurodegenerative disorder represented by the accumulation of intracellular tau protein and extracellular deposits of amyloid-β (Aβ) in the brain. The gene sortilin 1 (SORT1) has previously been associated with cardiovascular disease in gene association studies. It has also been proposed to be involved in AD pathogenesis through facilitating Aβ clearance by binding apoE/Aβ complexes prior to cellular uptake. However, the neuropathological role of SORT1 in AD is not fully understood. To evaluate the associations between gene variants of SORT1 and risk of AD, we performed genetic analyses in a Swedish case-control cohort. Ten single nucleotide polymorphisms (SNPs), covering the whole SORT1 gene, were selected and genotyped in 620 AD patients and 1107 controls. The SNP rs17646665, located in a non-coding region of the SORT1 gene, remained significantly associated with decreased risk of AD after multiple testing (pc=0.0061). In addition, other SNPs were found to be nominally associated with risk of AD, as well as altered cognitive function and the CSF biomarker Aβ42, but these associations did not survive correction for multiple testing. The fact that SORT1 has been strongly associated with risk of cardiovascular disease is intriguing as cardiovascular disease is also regarded as a risk factor for AD. Finally, increased knowledge about SORT1 function has a potential to increase our understanding of APOE, the strongest risk factor for AD.
  •  
2.
  •  
3.
  • Bjerke, Maria, 1977-, et al. (författare)
  • Cerebrospinal Fluid Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Combination with Subcortical and Cortical Biomarkers in Vascular Dementia and Alzheimer's Disease.
  • 2011
  • Ingår i: Journal of Alzheimer's disease : JAD. - 1387-2877. ; 27:3, s. 665-676
  • Tidskriftsartikel (refereegranskat)abstract
    • Alzheimer's disease (AD) and vascular dementia (VaD) are intertwined by mixed dementia (MD) harboring varying degrees of AD pathology in combination with cerebrovascular disease. The aim was to assess whether there is a difference in the cerebrospinal fluid (CSF) profile, of selected proteins, between patients with VaD and MD with subcortical vascular disease (SVD), AD, and healthy controls that could contribute in the separation of the groups. The study included 30 controls, 26 SVD patients (9 VaD and 17 MD) and 30 AD patients. The protein panel included total tau (T-tau), hyperphosphorylated tau 181 (P-tau181), amyloid β 1-42 (Aβ1-42), neurofilament light (NF-L), myelin basic protein (MBP), heart fatty acid binding protein (H-FABP), matrix metalloproteinases (MMP-1, -2, -3, -9, and -10), and tissue inhibitors of metalloproteinases (TIMP-1 and -2). Immunochemical methods were utilized for quantification of the proteins in CSF and data analysis was performed with a multivariate discriminant algorithm. The concentrations of MBP, TIMP-1, P-tau181, NF-L, T-tau, MMP-9, Aβ1-42, and MMP-2 contributed the most to the separation between SVD and AD, with a sensitivity of 89% and a specificity of 90% (AUC = 0.92). MBP and NF-L performed the best in discriminating SVD from controls, while T-tau and Aβ1-42 contributed the most in segregating AD from controls. The CSF biomarkers reflecting AD pathology (T-tau, P-tau181, and Aβ1-42), white matter lesions (NF-L and MBP) and matrix remodeling (MMP-9 and TIMP-1) perform well in differentiating between SVD and AD patients.
  •  
4.
  • Bjerke, Maria, 1977-, et al. (författare)
  • Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy.
  • 2014
  • Ingår i: Dementia and geriatric cognitive disorders extra. - 1664-5464. ; 4:3, s. 385-94
  • Tidskriftsartikel (refereegranskat)abstract
    • Small vessel disease (SVD) represents a common often progressive condition in elderly people contributing to cognitive disability. The relationship between cerebrospinal fluid (CSF) biomarkers and imaging correlates of SVD was investigated, and the findings were hypothesized to be associated with a neuropsychological profile of SVD.
  •  
5.
  • Bjerke, Maria, 1977-, et al. (författare)
  • Subcortical vascular dementia biomarker pattern in mild cognitive impairment.
  • 2009
  • Ingår i: Dementia and geriatric cognitive disorders. - 1421-9824. ; 28:4, s. 348-56
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Mild cognitive impairment (MCI) is an etiologically unclear disorder. Cerebrospinal fluid (CSF) biomarkers are potentially useful for the differentiation between various MCI etiologies. AIM: The aim of the study was to assess whether baseline CSF hyperphosphorylated tau (P-tau), total tau (T-tau), amyloid beta 1-42 (Abeta(42)) and neurofilament light (NF-L) in patients with MCI could predict subcortical vascular dementia (SVD) and Alzheimer's disease (AD) at follow-up. METHODS: Biomarker levels were assessed by Luminex xMAP technology and ELISA. RESULTS: Increased baseline concentrations of NF-L significantly separated MCI-SVD from stable MCI. The MCI-SVD patients were inseparable from stable MCI but separable from patients developing AD (MCI-AD) on the basis of Abeta(42,) T-tau and P-tau(181) levels. CONCLUSION: A combination of the biomarkers Abeta(42), T-tau, P-tau(181) and NF-L has the potential to improve the clinical separation of MCI-SVD patients from stable MCI and MCI-AD patients.
  •  
6.
  • Blennow, Kaj, 1958-, et al. (författare)
  • Evolution of Abeta42 and Abeta40 Levels and Abeta42/Abeta40 Ratio in Plasma during Progression of Alzheimer's Disease: A Multicenter Assessment.
  • 2009
  • Ingår i: The journal of nutrition, health & aging. - 1279-7707. ; 13:3, s. 205-8
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: To better understand the seemingly contradictory plasma beta-amyloid (Abeta) results in Alzheimer's disease (AD) patients by using a newly developed plasma Abeta assay, the INNO-BIA plasma Abeta forms, in a multicenter study. Methods: A combined retrospective analysis of plasma Abeta isoforms on mild cognitive impairment (MCI) from three large cross-sectional studies involving 643 samples from the participating German and Swedish centers. Results: Detection modules based on two different amino (N)-terminal specific Abeta monoclonal antibodies demonstrated that Abeta in plasma could be reliable quantified using a sandwich immunoassay technology with high precision, even for low Abeta42 plasma concentrations. Abeta40 and Abeta42 concentrations varied consistently with the ApoE genotype, while the Abeta42/Abeta40 ratio did not. Irrespective of the decrease of the Abeta42/Abeta40 ratio with age and MMSE, this parameter was strongly associated with AD, as defined in this study by elevated hyperphosphorylated (P-tau181P) levels in cerebrospinal fluid (CSF). Conclusion: A highly robust assay for repeatedly measuring Abeta forms in plasma such as INNO-BIA plasma Abeta forms might be a useful tool in a future risk assessment of AD.
  •  
7.
  •  
8.
  •  
9.
  • Brys, Miroslaw, et al. (författare)
  • Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease.
  • 2009
  • Ingår i: Journal of Alzheimer's disease : JAD. - 1387-2877. ; 16:2, s. 351-62
  • Tidskriftsartikel (refereegranskat)abstract
    • Little is known of combined utility of magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) biomarkers for prediction of Alzheimer's disease (AD) and longitudinal data is scarce. We examined these biomarkers at baseline and longitudinally in incipient AD. Forty-five subjects [21 controls (NL-NL), 16 stable MCI (MCI-MCI), 8 MCI who declined to AD (MCI-AD)] received MRI and lumbar puncture at baseline and after 2 years. CSF measures included total and phosphorylated tau (T-tau, P-tau(231)), amyloid-beta (Abeta(42)/Abeta(40)) and isoprostane. Voxel-based morphometry identified gray matter concentration (GMC) differences best distinguishing study groups and individual GMC values were calculated. Rate of medial temporal lobe (MTL) atrophy was examined using regional boundary shift (rBS) method. At baseline, for MRI, MCI-AD showed reduced GMC-MTL, and for CSF higher CSF T-tau, P-tau(231), IP and lower Abeta(42)/Abeta(40) as compared with MCI-MCI or NL-NL. Longitudinally, rBS-MTL atrophy was higher in MCI-AD than in either MCI-MCI or NL-NL, particularly in the left hemisphere. CSF data showed longitudinally greater increases of isoprostane in MCI-AD as compared with NL-NL. Combining baseline CSF-P-tau(231) and GMC-MTL significantly increased overall prediction of AD from 74% to 84% (p(step)<0.05). These results provide support for including multiple modalities of biomarkers in the identification of memory clinic patients at increased risk for dementia.
  •  
10.
  • Brys, Miroslaw, et al. (författare)
  • Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
  • 2009
  • Ingår i: Neurobiology of aging. - 1558-1497. ; 30:5, s. 682-90
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: To longitudinally evaluate five cerebrospinal fluid (CSF) biomarkers in the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD). METHODS: A baseline and 2-year follow-up clinical and CSF study of 86 subjects, including 22 MCI patients that declined to AD (MCI-AD), 43 MCI that did not deteriorate (MCI-MCI) and 21 controls (NL-NL). All subjects were studied for total and phosphorylated tau (T-tau, P-tau(231)), amyloid beta (Abeta) Abeta(42)/Abeta(40) ratio, isoprostane (IP) as well as P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios. RESULTS: At baseline and at follow-up MCI-AD showed higher levels P-tau(231), T-tau, IP, P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios and lower Abeta(42)/Abeta(40) than MCI-MCI or NL-NL. Baseline P-tau(231) best predicted MCI-AD (80%, p<0.001) followed in accuracy by P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios (both 75%, p's<0.001), T-tau (74%, p<0.001), Abeta(42)/Abeta(40) (69%, p<0.01), and IP (68%, p<0.01). Only IP showed longitudinal effects (p<0.05). CONCLUSIONS: P-tau(231) is the strongest predictor of the decline from MCI to AD. IP levels uniquely show longitudinal progression effects. These results suggest the use of CSF biomarkers in secondary prevention trials.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 43
Åtkomst
fritt online (1)
Typ av publikation
tidskriftsartikel (39)
forskningsöversikt (4)
Typ av innehåll
Författare/redaktör
Zetterberg, Henrik, ... (28)
Edman, Åke, (11)
Rolstad, Sindre, 197 ... (11)
Nordlund, Arto, 1962 ... (9)
visa fler...
Bjerke, Maria, 1977- ... (9)
Jonsson, Michael, 19 ... (8)
Eckerström, Carl, (8)
Lind, Karin, 1952-, (7)
Andreasson, Ulf, 196 ... (6)
Hampel, Harald (4)
Shen, Yong (4)
Hansson, O (3)
Höglund, Kina, 1976- ... (3)
Minthon, Lennart, 19 ... (3)
Olsson, Erik, 1960-, (3)
Sjögren, Magnus (3)
Göthlin, Mattias, 19 ... (3)
Öhrfelt Olsson, Anni ... (3)
Syversen, Steinar, 1 ... (3)
Minthon, L (2)
Rosengren, Lars, 195 ... (2)
Brinkmalm-Westman, A ... (2)
Herukka, S K (2)
Haghighi, Sara, (2)
Olsson, Bob, 1969-, (2)
Karlsson, I (2)
Johansson, Boo (2)
Vanderstichele, H (2)
Vanmechelen, E (2)
Lautner, Ronald, (2)
Mattsson, Niklas, 19 ... (2)
Hampel, H. (2)
Rüetschi, Ulla, 1962 ... (2)
Pantoni, L (2)
Inzitari, D (2)
Svensson, Johan, 196 ... (2)
de Leon, Mony J (2)
Rasulzada, Abdullah (2)
Popa, Cornel, 1980- (2)
Brys, Miroslaw (2)
Mosconi, Lisa (2)
Switalski, Remigiusz (2)
De Santi, Susan (2)
Pirraglia, Elizabeth (2)
Rich, Kenneth (2)
Mehta, Pankaj (2)
Zinkowski, Ray (2)
Pratico, Domenico (2)
visa färre...
Lärosäte
Göteborgs universitet (43)
Lunds universitet (1)
Chalmers tekniska högskola (1)
Karolinska Institutet (1)
Språk
Engelska (39)
Svenska (3)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (43)
Samhällsvetenskap (3)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy